The Pharmacy Compounding Advisory Committee (PCAC) is the FDA committee that votes on which substances belong on the Section 503A bulk drug substances list and where they sit (Category 1, 2, or 3). It is the formal venue where research-peptide policy gets made.
The July 23-24, 2026 peptide session at FDA's White Oak Campus in Silver Spring, Maryland (docket FDA-2025-N-6895) is the most consequential PCAC meeting in the site's coverage window. The two-day tally: 6 of 7 peptides recommended for 503A. Day 1 (July 23) cleared all four peptides on the docket: BPC-157 (8-6 with 1 abstention), KPV (8-6 with 1 abstention), TB-500 (8-6), and MOTS-c (7-5 with 2 abstentions). Day 2 (July 24) recommended Semax 8-5 for cerebral ischemia, migraine, and trigeminal neuralgia, recommended Epitalon 7-4 for insomnia, and narrowly rejected Emideltide (delta sleep-inducing peptide, DSIP) — the sole no vote of the two-day session. Every one of the 6 wins overrode the FDA career-staff briefing documents released June 29-30 that recommended against adding any of the seven peptides, citing immunogenicity, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use.
Panel composition shaped the outcome. The FDA named eight new PCAC members on June 29 to fill the peptide-session seats; at least seven have documented ties to peptide-related businesses per STAT News reporting, including Tennessee state senator Bobby Harshbarger and clinicians who run high-price peptide consultations. Time Magazine framed the vote as 'an FDA committee voting in favor of peptides despite the agency's opposition.' PCAC recommendations are advisory, not binding; formal FDA rulemaking to add a substance takes approximately 6 to 18 months. Stories here cover meeting minutes, vote outcomes, public comments, and the petitions that drive new substances onto the agenda. See [[503a-bulks-list]] and [[fda-pcac]] for adjacent threads.
A Bloomberg opinion piece published April 21 argues that the FDA's planned July 23-24 PCAC review of seven peptides (BPC-157, MOTS-c, KPV, among others) and RFK Jr.'s broader push to reclassify 14 of 19 Category 2 peptides doesn't give consumers the evidence-based safety and efficacy data they need. The piece frames the ongoing compounding debate as a consumer-protection gap that clinical trial evidence — not political reclassification — should fill.
A BioCentury analysis argues the FDA's April 16 decision to convene a July Pharmacy Compounding Advisory Committee meeting on 12 previously restricted peptides reflects HHS Secretary RFK Jr.'s enthusiasm more than scientific evidence. The outlet warns that most of the peptides under review — for conditions spanning ulcerative colitis, wound healing, obesity, insomnia, and neurological disorders — lack robust clinical safety or efficacy data, and that ideology is increasingly shaping agency decisions.
STAT News analysis of the composition of the July 23-24 Pharmacy Compounding Advisory Committee suggests panelists are likely to vote in favor of broader peptide access. The panel will review BPC-157 (ulcerative colitis), KPV (wound healing), TB-500, MOTS-c, emideltide, semax, and epitalon — largely aligning with RFK Jr.'s February 2026 pledge to move 14 restricted peptides back to Category 1.
The FDA announced it will convene the Pharmacy Compounding Advisory Committee on July 23-24 to evaluate whether seven or more peptides — including BPC-157, TB-500, and other popular wellness peptides — should be added to the list of substances eligible for pharmacy compounding. The announcement follows HHS Secretary RFK Jr.'s February pledge to reclassify 14 restricted peptides.